FDA Approves Iberdomide Plus Daratumumab and Dexamethasone for Multiple Myeloma (oncologynewscentral.com)
Learn about the FDA approval of iberdomide plus daratumumab and hyaluronidase-fihj and dexamethasone for treating multiple myeloma, offering new hope for patients with relapsed or refractory disease.
A new class of multiple myeloma treatment has arrived. The FDA has approved Zenbexus in combination therapy for previously treated patients, the first approved CELMoD protein degrader for multiple myeloma.
www.oncologynewscentral.com/drugs/info/f...
